This disruption is associated with elevated activity in pro-inflammatory pathways, such as JAK-STAT, NF-κB, and MAPK, alongside alterations in IL-6 and TGF-β2, which may contribute to myocardial fibrosis and hypertrophy in HCM. The gene discussed is TGFB2; the disease is Myocardial fibrosis.